Kymab Ltd. CEO Dr David Chiswell OBE has more than 30 years of experience in the biotechnology industry, having co-founded Cambridge Antibody Technology Group PLC in 1990, a company that originated one of the world’s biggest selling drugs, Humira (adalimumab). CAT was sold to AstraZeneca PLC in 2006 for £702m, and it now forms an important part of its biopharmaceutical franchise.
Since leaving CAT in 2002, he has focused on the development of early-stage biotechnology companies, having previously served as a...